One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
The immunotherapy challenge in locally advanced gastroesophageal cancer: VESTIGE trial’s insights and future pathways
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy☆
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
Authors’ reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study
Time to rethink platinum choices in the era of immunotherapy in lung cancer
PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?
Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto
Reply to the Letter to the Editor “Odronextamab against relapsed or refractory follicular lymphoma� by Y. Shimazu
Circulating tumor DNA after definitive therapy for locally advanced rectal cancer
Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima
Promising response to lurbinectedin in NUT carcinoma: a case report and review of emerging therapeutic strategies
Chi-square and P-values versus machine learning feature selection
Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’
